OTC

Neureliv 50 mg

Incepta Pharmaceuticals Ltd. · Tablet

GenericEpalrestat

Strength50 mg

Total Strip3

Strip Size10

Unit Price

৳ 10

/ Piece

Order Now

⚠ Disclaimer

The information provided on All Samadhan is intended for general informational purposes only and is prepared based on our best practices. It is not a substitute for professional medical advice, diagnosis, or treatment. While we strive to keep the information accurate and up to date, we do not guarantee its completeness or accuracy. The absence of specific information or warnings about any medicine or service should not be considered as an assurance or endorsement by All Samadhan. All Samadhan shall not be held responsible for any consequences arising from the use of this information. We strongly recommend consulting a qualified healthcare professional or physician for any medical concerns, questions, or clarifications.

Medicine Description

INDICATIONS

Epalrestat is indicated for the improvement of subjective symptoms (numbness and pain), abnormality of vibration sense and abnormal change in heartbeat associated with diabetic peripheral neuropathy (when high glycohemoglobin value is noted).

PHARMACOLOGY

Epalrestat specifically inhibits aldose reductase and accumulation of sorbitol in the nerve; thereby improves subjective symptoms and nerve dysfunction in patients with diabetic peripheral neuropathy.

DOSAGE & ADMINISTRATION

The usual adult dose is 1 tablet (50 mg) three times daily before each meal. The dosage may be adjusted according to the patient's age and symptoms.

INTERACTION

There are no known drug interactions and none well documented.

SIDE EFFECTS

Major adverse reactions are hepatic function abnormalities and thrombocytopenia. In cases of hepatic abnormalities drug should be discontinued immediately and appropriate measures should be taken. Other reactions may be malaise, headache, abdominal pain, nausea, hypersensitivity reaction etc.

PREGNANCY & LACTATION

The safety of epalrestat in pregnant women has not been established. The drug may be used in pregnant women or in women who may possibly be pregnant only if expected therapeutic benefits outweigh the possible risks associated with the treatment. Breast-feeding should be avoided during administration of epalrestat.

PRECAUTIONS & WARNINGS

The administration of Epalrestat should be considered to patients showing high glycohemoglobin values even after fundamental therapies for diabetes mellitus such as diet therapy, exercise therapy and treatment with an oral hypoglycemic agent, insulin etc. The efficacy of this product has not been established in patients with diabetic peripheral neuropathy with irreversible organic changes. The patient should be carefully monitored during the administration of this product. When the efficacy of this product is not observed even after 12 weeks of administration, other appropriate therapies should be taken.